Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-Indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(fu ro[2,3-B]pyridin-5-YL)methyl]piperazin-1-YL]-4(S)-hydroxy-2(R)-phenylmethylpe ntanamide and p-glycoprotein by valspodar in gene transfectant systems

Drug Metabolism and Disposition

Volumn 28, Issue 10, 2000, Pages 1238-1243

  Kawahara, Iichiro ^a   Kato, Yukio ^a   Suzuki, Hiroshi ^a   Achira, Meguru ^a   Ito, Kiyomi ^a   Crespi, Charles L ^b   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Gentest Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A4; DIGOXIN; GLYCOPROTEIN P; KETOCONAZOLE; L 754394; MIDAZOLAM; N [2 HYDROXY 1 INDANYL] 5 [2(1,1 DIMETHYLETHYLAMINOCARBONYL) 4 [FURO[2,3 B]PYRIDIN 5 YL METHYL]PIPERAZIN 1 YL] 4 HYDROXY 2 PHENYLMETHYLPENTANAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME INHIBITION; ENZYME SPECIFICITY; FIRST PASS EFFECT; GENETIC TRANSFECTION; JEJUNUM; MICROSOME; NONHUMAN; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL LINE; CYCLOSPORINS; CYTOCHROME P-450 ENZYME SYSTEM; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYLATION; INDANS; MICROSOMES; MIDAZOLAM; MIXED FUNCTION OXYGENASES; P-GLYCOPROTEIN; PIPERAZINES; RECOMBINANT PROTEINS; TRANSFECTION;

ANIMALIA;

EID: 0033810576     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P450 3A4
2. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane
3. Potent and selective inactivation of human fiver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor
4. Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4
5. Cytochrome P-450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues
6. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
7. The effects of ketoconazole on the intestinal metabolism and bioavailabillty of cyclosporine
8. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
9. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers
10. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach
11. SDZ PSC 833, a non-immunosuppressive cyclosporin: Its potency in overcoming P-glycoprotein mediated multidrug resistance of murine leukemia
12. First-pass metabolism of cyclosporin by the gut
13. Substrates of human hepatic cytochrome P450 3A4
14. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
15. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
16. Protein measurement with Folin phenol reagent
17. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
18. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine
19. Absence of the mdr1 a P-glycoprotein in Mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
20. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum
21. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
22. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier
23. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
24. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents
25. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implication for drug discovery and activity in cancer chemotherapy
26. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo
27. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man
28. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine
29. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats